BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

867 related articles for article (PubMed ID: 29869757)

  • 21. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
    Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
    Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
    Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
    J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy.
    Sutton PA; O'Dwyer ST; Barriuso J; Aziz O; Selvasekar CR; Renehan AG; Wilson MS
    Surg Oncol; 2021 Sep; 38():101572. PubMed ID: 33915487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
    Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
    Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment-Related Mortality After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis is Underestimated by Conventional Parameters.
    Simkens GA; van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2016 Jan; 23(1):99-105. PubMed ID: 26148758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies.
    Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comprehensive review of childbearing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Papageorgiou D; Manatakis DK; Papakonstantinou K; Kyriazanos ID
    Arch Gynecol Obstet; 2020 Oct; 302(4):793-799. PubMed ID: 32653946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
    Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
    Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results.
    Golse N; Bakrin N; Passot G; Mohamed F; Vaudoyer D; Gilly FN; Glehen O; Cotte E
    J Surg Oncol; 2012 Aug; 106(2):197-203. PubMed ID: 22331814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
    Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
    Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases.
    Choudry HA; Bednar F; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2019 May; 26(5):1445-1453. PubMed ID: 30825033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
    Huang Y; Alzahrani NA; Liauw W; Morris DL
    Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
    Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
    Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases.
    Kyang LS; Alzahrani NA; Valle SJ; Rahman MK; Arrowaili A; Liauw W; Morris DL
    J Surg Oncol; 2019 Sep; 120(4):794-802. PubMed ID: 31309588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.
    Chang SC; Fingerhut A; Chen WT
    Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Ahmed S; Levine EA; Randle RW; Swett KR; Shen P; Stewart JH; Votanopoulos KI
    Ann Surg Oncol; 2014 Dec; 21(13):4226-31. PubMed ID: 25034815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases.
    Votanopoulos KI; Russell G; Randle RW; Shen P; Stewart JH; Levine EA
    Ann Surg Oncol; 2015 Apr; 22(4):1274-9. PubMed ID: 25319583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of Absent Neoplastic Epithelium in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Enblad M; Birgisson H; Wanders A; Sköldberg F; Ghanipour L; Graf W
    Ann Surg Oncol; 2016 Apr; 23(4):1149-56. PubMed ID: 26577120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hematological toxicities associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Wong EYT; Tan GHC; Kumar M; Teo MCC
    Asia Pac J Clin Oncol; 2020 Apr; 16(2):e38-e46. PubMed ID: 31693307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.